Evidence map›Paper›PMID 32558036›Full record

Observational studyPharmacoepidemiology and drug safety2020

Opioid, gabapentinoid, and nonsteroidal anti-inflammatory medication use and the risks of atrial fibrillation and supraventricular ectopy in the Multi-Ethnic Study of Atherosclerosis.

Barbara N Harding, Kerri L Wiggins, Paul N Jensen, Barbara McKnight, Bruce M Psaty, Susan R Heckbert, James S Floyd

Open access · greenAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Pharmacoepidemiology and drug safety, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Atrial fibrillation induced by gabapentin: a case report.Journal of medical case reports · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Barbara N HardingCardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, Washington, USA.ORCID 0000-0002-9460-9399
Kerri L WigginsCardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, Washington, USA.
Paul N JensenCardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, Washington, USA.
Barbara McKnightCardiovascular Health Research Unit and Department of Biostatistics, University of Washington, Seattle, Washington, USA.
Bruce M PsatyCardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, Washington, USA.
Susan R HeckbertCardiovascular Health Research Unit and Department of Epidemiology, University of Washington, Seattle, Washington, USA.
James S FloydCardiovascular Health Research Unit and Department of Medicine, University of Washington, Seattle, Washington, USA.
University of Washington · USKaiser Permanente Washington Health Research Institute · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
QAQC Johns Hopkins Institute for Clinical and Translational ResearchUL1TR003098 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2019 to 2023
$57.7M
Translational Research Support CoreP30ES000002 · NIEHS · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI JAIME ELIZABETH HART · 1985 to 2026
$44.6M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Task Area A Core Study Operations.Task Area A shall encompass annual follow-up of cohort members, clinical endpoints ascertainment, study coordination activities, maintenance of the database and biosp75N92020D00001 · NHLBI · UNIVERSITY OF WASHINGTON · PI MCCLELLAND, ROBYN LEAGH · 2020 to 2025
$17.2M
CARDIOVASCULAR RESEARCH TRAINING PROGRAMT32HL007828 · NHLBI · UNIVERSITY OF WASHINGTON · PI Francis Kim, Farid Moussavi-Harami · 1997 to 2026
$10.2M
CARDIOVASCULAR HEALTH STUDY (CHS) - TASK AREA C, STUDY CLOSEOUT75N92021D00006 · NHLBI · UNIVERSITY OF WASHINGTON · PI PSATY, BRUCE · 2021 to 2024
$8.4M
Atrial fibrillation burden, vascular disease of the brain and cardiac MRI in MESAR01HL127659 · NHLBI · UNIVERSITY OF WASHINGTON · PI HECKBERT, SUSAN R · 2015 to 2018
$7.4M
Task Area A shall encompass annual follow-up of cohort members, clinical events investigations, study operations, and data analysis and manuscript writing. If implemented, Task A.1 will provide fundin75N92020D00005 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI WATSON, KAROL E · 2020 to 2025
$5.1M
Subclinical Atrial Fibrillation and Supraventricular Ectopy in the Jackson Heart StudyR01HL142599 · NHLBI · UNIVERSITY OF WASHINGTON · PI FLOYD, JAMES S · 2018 to 2022
$4.9M
TO EXERCISE OPTION PERIOD ONE (1) FOR TASK AREA A - MESA CORE OPERATIONS, FIELD CENTER.75N92020D00004 · NHLBI · NORTHWESTERN UNIVERSITY · PI SIEGEL, JONATHAN H · 2020 to 2025
$4.5M
CLC NIH HHS 75N90020D00002CLC NIH HHS 75N90020D00003NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1-TR-000040NCATS NIH HHS UL1 TR001079NCATS NIH HHS UL1-TR-001079NCATS NIH HHS UL1 TR001420NCATS NIH HHS UL1-TR-001420NCATS NIH HHS UL1 TR003098NHLBI NIH HHS 75N92020D00001NHLBI NIH HHS 75N92020D00002NHLBI NIH HHS 75N92020D00003NHLBI NIH HHS 75N92020D00004NHLBI NIH HHS 75N92020D00005NHLBI NIH HHS 75N92020D00006NHLBI NIH HHS 75N92020D00007NHLBI NIH HHS 75N92021D00006NHLBI NIH HHS HHSN268201500003CNHLBI NIH HHS HHSN268201500003INHLBI NIH HHS K08 HL116640NHLBI NIH HHS K08HL116640NHLBI NIH HHS N01 HC095159NHLBI NIH HHS N01 HC095160NHLBI NIH HHS N01 HC095161NHLBI NIH HHS N01 HC095162NHLBI NIH HHS N01 HC095163NHLBI NIH HHS N01 HC095164NHLBI NIH HHS N01 HC095165NHLBI NIH HHS N01 HC095166NHLBI NIH HHS N01 HC095167NHLBI NIH HHS N01 HC095168NHLBI NIH HHS N01 HC095169NHLBI NIH HHS N01-HC-95159NHLBI NIH HHS N01-HC-95160NHLBI NIH HHS N01-HC-95161NHLBI NIH HHS N01-HC-95162NHLBI NIH HHS N01-HC-95163NHLBI NIH HHS N01-HC-95164NHLBI NIH HHS N01-HC-95165NHLBI NIH HHS N01-HC-95166NHLBI NIH HHS N01-HC-95167NHLBI NIH HHS N01-HC-95168NHLBI NIH HHS N01-HC-95169NHLBI NIH HHS R01 HL127659NHLBI NIH HHS R01HL127659NHLBI NIH HHS R01 HL142599NHLBI NIH HHS R01HL142599NHLBI NIH HHS T32 HL007828NHLBI NIH HHS T32HL007828NIAID NIH HHS 75N93020D00002NIDA NIH HHS 75N95020D00002NIDA NIH HHS 75N95020D00003NIDA NIH HHS 75N95020D00004NIDA NIH HHS 75N95020D00005NIDA NIH HHS 75N95020D00007NIEHS NIH HHS 75N96020D00002NIEHS NIH HHS 75N96020D00003NIH HHS 75N98020D00007ORFDO NIH HHS 75N99020D00002ORFDO NIH HHS 75N99020D00003ORFDO NIH HHS 75N99020D00004ORFDO NIH HHS 75N99020D00005ORFDO NIH HHS 75N99020D00006ORFDO NIH HHS 75N99020D00007
6 · The paper itself

Abstract

purposeOpioids, gabapentinoids, and nonsteroidal anti-inflammatory drugs (NSAIDs) may have adverse cardiovascular effects. We evaluated whether these medications were associated with incident clinically detected atrial fibrillation (AF) or monitor-detected supraventricular ectopy (SVE), including premature atrial contractions (PACs) and supraventricular tachycardia (SVT).

methodsWe used data from the Multi-Ethnic Study of Atherosclerosis (MESA), a cohort study that enrolled 6814 Americans without clinically detected cardiovascular disease in 2000 to 2002. At the 2016 to 2018 examination, 1557 individuals received ambulatory electrocardiographic (ECG) monitoring. Longitudinal analyses investigated time-varying medication exposures at the first five exams (through 2011) in relation to incident clinically detected AF through 2015 using Cox proportional hazards regression models. Cross-sectional analyses investigated medication exposures at 2016 to 2018 examination and the risk of monitor-detected SVE using linear regression models.

resultsThe longitudinal cohort included 6652 participants. During 12.4 years of mean follow-up, 982 participants (14.7%) experienced incident clinically detected AF. Use of opioids, gabapentinoids, and NSAIDs were not associated with incident AF. The cross-sectional analysis included 1435 participants with ECG monitoring. Gabapentinoid use was associated with an 84% greater average frequency of PACs/hour (95% CI, 25%-171%) and a 44% greater average number of runs of SVT/day (95% CI, 3%-100%). No associations were found with use of opioids or NSAIDs in cross-sectional analyses.

conclusionsIn this study, gabapentinoid use was associated with SVE. Given the rapid increase in gabapentinoid use, additional studies are needed to clarify whether these medications cause cardiovascular complications.

Indexed as

AgedAged, 80 and overAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalAtherosclerosisAtrial FibrillationAtrial Premature ComplexesCross-Sectional StudiesElectrocardiography, AmbulatoryFemaleGabapentinHumansIncidenceLongitudinal StudiesMaleMiddle AgedAnalgesics, OpioidAnti-Inflammatory Agents, Non-SteroidalGabapentinarrhythmiaatrial fibrillationcohort studygabapentinoidopioidpharmacoepidemiologysupraventricular tachycardia

Identifiers

PMID32558036
PMCPMC7933496
OpenAlexW3036572296

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.